The big one is CMS and it's not even close IMO. The proposal also trumps the Medtronic deal since it may lead to **forced** product behavior changes. If the proposal to limit grafts is introduced, It will be interesting how the stock responds short term. There could be initial confusion by weak hands who may be concerned over margins and may not see the big picture with regards to a potential windfall of marketshare (increasing revenue projections) via new CMS rule(s). Brace yourself, it should be interesting. Good luck, I'm betting CMS will be a catalyst as I'm reading between the lines of Pete's non-defensive letter to CMS.
You don't think 2/3 items you mentioned will significantly move the price? I have been thinking the CMS decision due out on 11/27 would be a big event, as would any FDA decision. Regardless of the magnitude of their impact, knowing both outcomes would remove the majority of the uncertainty that remains.
Based on the last several earnings reports, there doesn't seem to be much correlation with stock movement, at least increased stock price. We need more analysts following the stock which is difficult for a small cap. Good news from the MACs and FDA would help but good news seems baked into the stock price and bad news doesn't. I'm not looking for FDA news, good, bad or indifferent, until Q1. I hope I'm wrong but I think we'e in a two year slog to $10. $10 from here is an 82% increase, great performance but we've been spoiled over the last two years.